ZYXI vs. AXGN, EDAP, SMLR, ELMD, OM, FONR, VANI, CUTR, BLFS, and DCGO
Should you be buying Zynex stock or one of its competitors? The main competitors of Zynex include AxoGen (AXGN), Edap Tms (EDAP), Semler Scientific (SMLR), Electromed (ELMD), Outset Medical (OM), FONAR (FONR), Vivani Medical (VANI), Cutera (CUTR), BioLife Solutions (BLFS), and DocGo (DCGO).
Zynex (NASDAQ:ZYXI) and AxoGen (NASDAQ:AXGN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, community ranking, institutional ownership, profitability, valuation, analyst recommendations and media sentiment.
Zynex currently has a consensus target price of $18.00, suggesting a potential upside of 65.75%. AxoGen has a consensus target price of $10.67, suggesting a potential upside of 91.16%. Given AxoGen's higher probable upside, analysts plainly believe AxoGen is more favorable than Zynex.
AxoGen received 423 more outperform votes than Zynex when rated by MarketBeat users. Likewise, 72.59% of users gave AxoGen an outperform vote while only 51.16% of users gave Zynex an outperform vote.
Zynex has a net margin of 4.33% compared to AxoGen's net margin of -12.99%. Zynex's return on equity of 16.34% beat AxoGen's return on equity.
Zynex has higher revenue and earnings than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than Zynex, indicating that it is currently the more affordable of the two stocks.
29.7% of Zynex shares are held by institutional investors. Comparatively, 80.3% of AxoGen shares are held by institutional investors. 52.1% of Zynex shares are held by company insiders. Comparatively, 7.0% of AxoGen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
In the previous week, Zynex had 12 more articles in the media than AxoGen. MarketBeat recorded 22 mentions for Zynex and 10 mentions for AxoGen. Zynex's average media sentiment score of 0.33 beat AxoGen's score of -0.23 indicating that Zynex is being referred to more favorably in the media.
Zynex has a beta of 0.49, meaning that its stock price is 51% less volatile than the S&P 500. Comparatively, AxoGen has a beta of 1.07, meaning that its stock price is 7% more volatile than the S&P 500.
Summary
Zynex beats AxoGen on 11 of the 17 factors compared between the two stocks.
Get Zynex News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZYXI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ZYXI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
